1. Home
  2. TIL vs NHS Comparison

TIL vs NHS Comparison

Compare TIL & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TIL
  • NHS
  • Stock Information
  • Founded
  • TIL 2018
  • NHS 2003
  • Country
  • TIL United States
  • NHS United States
  • Employees
  • TIL N/A
  • NHS N/A
  • Industry
  • TIL Biotechnology: Pharmaceutical Preparations
  • NHS Trusts Except Educational Religious and Charitable
  • Sector
  • TIL Health Care
  • NHS Finance
  • Exchange
  • TIL Nasdaq
  • NHS Nasdaq
  • Market Cap
  • TIL 230.1M
  • NHS 221.6M
  • IPO Year
  • TIL 2021
  • NHS N/A
  • Fundamental
  • Price
  • TIL $23.14
  • NHS $7.54
  • Analyst Decision
  • TIL Buy
  • NHS
  • Analyst Count
  • TIL 5
  • NHS 0
  • Target Price
  • TIL $119.00
  • NHS N/A
  • AVG Volume (30 Days)
  • TIL 387.8K
  • NHS 111.8K
  • Earning Date
  • TIL 08-12-2025
  • NHS 01-01-0001
  • Dividend Yield
  • TIL N/A
  • NHS 13.44%
  • EPS Growth
  • TIL N/A
  • NHS N/A
  • EPS
  • TIL N/A
  • NHS N/A
  • Revenue
  • TIL N/A
  • NHS N/A
  • Revenue This Year
  • TIL N/A
  • NHS N/A
  • Revenue Next Year
  • TIL N/A
  • NHS N/A
  • P/E Ratio
  • TIL N/A
  • NHS N/A
  • Revenue Growth
  • TIL N/A
  • NHS N/A
  • 52 Week Low
  • TIL $9.62
  • NHS $6.95
  • 52 Week High
  • TIL $92.00
  • NHS $9.17
  • Technical
  • Relative Strength Index (RSI)
  • TIL 43.15
  • NHS 44.95
  • Support Level
  • TIL $21.29
  • NHS $7.37
  • Resistance Level
  • TIL $31.67
  • NHS $7.51
  • Average True Range (ATR)
  • TIL 3.95
  • NHS 0.07
  • MACD
  • TIL -1.71
  • NHS -0.02
  • Stochastic Oscillator
  • TIL 8.60
  • NHS 26.47

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

About NHS Neuberger Berman High Yield Strategies Fund

Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.

Share on Social Networks: